FEATURED

DaVita Is Down. The Medicaid Clock Is the Reason.

DaVita dropped sharply in premarket trading and has held those losses through the session. One of the worst performers in the market today, with no company-specific earnings or guidance driving it. The selling is purely policy-driven, and it has a specific clock attached to it.

Here is what is actually happening.

The Trump administration’s One Big Beautiful Bill Act, signed into law on July 4, 2025, established mandatory Medicaid work requirements. CMS released the implementing interim final rule on June 1, 2026. The rule takes effect July 31, 2026. States must have requirements in place by January 1, 2027, though several are already moving faster. Nebraska went live May 1. Montana and Arkansas both launched July 1. Under the rule, certain adult Medicaid applicants aged 19 through 64 must meet an 80-hour-per-month community engagement threshold through employment, education, or qualifying service activities to maintain coverage.

The problem for DaVita is structural. In 2025, 89% of DaVita’s patients were covered by government-based health insurance programs. Government payers, including Medicare and Medicaid, accounted for 68% of total revenues. But here is the part that stings: commercial payers, which made up just 32% of 2025 revenues, generate nearly all of the company’s profit because they reimburse at dramatically higher rates than government programs. Anything that pushes patients out of commercial or even stable Medicaid coverage and into uninsured or emergency-only status hits DaVita’s margin structure directly.

Dialysis is not optional. Patients on in-center hemodialysis attend treatment three times per week. Fatigue and cardiovascular complications limit capacity on treatment days. The National Kidney Foundation has been clear that the 80-hour monthly threshold is not a realistic standard for this patient population. And with the June 2026 rule defining medical frailty more narrowly than many states and stakeholders expected, whether a dialysis patient qualifies for automatic exemption will be decided state by state. That creates a patchwork, and patchwork creates coverage risk.

This is not just a dialysis story. The administrative complexity of implementing these requirements is so significant that even patients who are technically exempt are at risk of losing coverage through paperwork failures and missed notices. States that go live in January 2027 were required to begin sending outreach notices to enrollees by late summer 2026. That clock is already running.

The math runs directly through DaVita’s revenue line. When a patient transitions from commercial coverage to Medicare or Medicaid, DaVita absorbs a reimbursement step-down. If Medicaid coverage disruptions push patients into uninsured or emergency-care status, DaVita absorbs uncompensated care. If patients lose coverage and delay treatment, clinical outcomes deteriorate and the volume picture gets complicated fast.

The business itself is not broken. Q1 2026 revenue came in at $3.42 billion, up 5.9% year over year. Diluted EPS of $2.87 beat consensus by roughly 23%. Full-year 2025 free cash flow was $1.024 billion. DaVita has an active $2 billion share buyback program and repurchased 3.0 million shares in Q1 2026 alone at an average price of $133.70. After Q1, management raised full-year 2026 adjusted EPS guidance to $14.10-$15.20. TD Cowen lifted its price target to $201 from $144 post-earnings.

But the Medicaid policy risk is no longer theoretical. It is arriving on a published, legislated timeline. The interim final rule comment period closes July 31. States begin full implementation January 1. The market is adjusting for that transition today.

What matters next: CMS’s own projections, embedded in the June 2026 interim final rule, estimate that roughly 2.3 million people will be disenrolled from Medicaid in fiscal year 2027 due to the work requirement, growing to between 3.1 and 3.3 million in subsequent years. The CBO’s broader estimate puts total Medicaid coverage losses from the full bill at around 5.2 million over time. Not all of those are dialysis patients. But the share that are, and exactly how DaVita’s payer mix shifts in response, is the question Q2 earnings in early August will need to address head-on.

The underlying dialysis demand is not going away. End-stage renal disease does not respond to policy. What changes is who pays for it, and how much. That is the number worth watching.